Pfizer Animal Health may divest some products

Pfizer Animal Health may have to divest some of its products if plans to takeover Wyeth are to be approved, it has been reported.

The Wall Street Journal explained how the former’s chief financial officer Frank D’Anelio made this announcement at yesterday’s Cowen & Company’s Annual Health Care Conference.

In January this year, Pfizer agreed to buy Wyeth, but now it may need to address a number of issues with regards to both firms’ portfolios if it is to get authorisation for the acquisition from the government.

Some of the animal products made by the two companies overlap and this may lead to an inspection by the Federal Trade Commission.

If divestitures are needed, it should not account for more than ten per cent of the units’ combined revenues generated in 2008, the newspaper recorded Mr D’Anelio as explaining.

Pfizer Animal Genetics announced at the beginning of the year that the company’s GeneStar MVP ? a molecular value prediction ? is now available for industry professionals to provide information about the relevant traits of animal feeds, among other things.